Autolus Therapeutics (NASDAQ:AUTL) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note released on Monday,Benzinga reports. Needham & Company LLC currently has a $10.00 price target on the stock.

Several other equities research analysts have also issued reports on the company. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Friday, November 15th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $2.33 on Monday. The company has a market capitalization of $620.00 million, a price-to-earnings ratio of -1.93 and a beta of 2.05. Autolus Therapeutics has a 52-week low of $2.07 and a 52-week high of $7.37. The company has a 50-day simple moving average of $2.76 and a two-hundred day simple moving average of $3.58.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the firm posted ($0.26) earnings per share. On average, sell-side analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. ProShare Advisors LLC purchased a new stake in Autolus Therapeutics in the 2nd quarter worth about $43,000. Arkadios Wealth Advisors bought a new position in Autolus Therapeutics during the fourth quarter worth about $47,000. Capstone Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the third quarter worth about $51,000. Daiwa Securities Group Inc. increased its stake in shares of Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Autolus Therapeutics in the fourth quarter valued at approximately $75,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.